Business Segment (Tables)

6 Months Ended

12 Months Ended

Jun. 30, 2023

Dec. 31, 2022

Business Segment [Abstract]

Schedule of Operations by Business Segment

Summarized below is information about the Company’s operations for the three and six months ended June 30, 2023 and 2022 by business segment:

	Three Months Ended June 30,										Six Months Ended June 30,
	Revenue				Earnings						Revenue				Earnings
	2023		2022		2023			2022			2023		2022		2023			2022
FOXO Labs	$	7	$	32	$	(314	)	$	(948	)	$	14	$	64	$	(604	)	$	(1,452	)
FOXO Life		5		7		(243	)		(1,109	)		11		15		(890	)		(1,912	)
		12		39		(557	)		(2,057	)		25		79		(1,494	)		(3,364	)
Impairment (a)						(2,633	)		-							(2,633	)		-
Stock issuances (b)						(3,521	)		-							(3,521	)		-
Corporate and other (c)						(4,090	)		(20,978	)						(10,567	)		(31,716	)
Interest expense						(492	)		(504	)						(717	)		(826	)
Total	$	12	$	39	$	(11,293	)	$	(23,539	)	$	25	$	79	$	(18,932	)	$	(35,906	)

(a) See Note 4 for additional information on the digital insurance platform, underwriting API, and longevity API impairment.

(b) Stock issuances includes the 2022 Bridge Debenture Release and the PIK Note Amendment. See Notes 5 and 7 for additional information.

(c) Corporate and other includes stock-based compensation, including the Consulting Agreement, expense of $1,268 and depreciation and amortization expense of $247 for the three months ended June 30, 2023 with corresponding amounts of $3,894 and $1,176 for the six months ended June 30, 2023. For the three months ended June 30, 2022 corporate and other included stock-based compensation, depreciation, and changes in fair value of the convertible debentures of $1,459, $55, and $17,051 respectively. The corresponding amounts for the six months ended June 30, 2022 are $1,690, $86, and $24,483, respectively with stock-based compensation. Both the three and six months ended June 30, 2022 included $1,229 of stock-based compensation related to the Consulting Agreement. See Notes 4, 6, and 9 for additional information.

Summarized below is information about the Company’s operations for the years ended December 31, 2022 and 2021 by business segment:

	Revenue				Earnings
	2022		2021		2022			2021
FOXO Labs	$	483	$	85	$	(2,769	)	$	(4,790	)
FOXO Life		28		35		(3,735	)		(2,381	)
		511		120		(6,504	)		(7,171	)
Corporate and other (a)						(87,311	)		(30,199	)
Interest expense						(1,440	)		(1,118	)
Total	$	511	$	120	$	(95,255	)	$	(38,488	)

(a) Corporate and other includes stock-based compensation, including the consulting agreement, Cantor Commitment Fee and vendor shares, expense of $17,708, depreciation and amortization expense of $1,487, change in fair value of convertible debentures and warrant liability expense of $26,104, $1,307 for impairment charge and $27,544 of other non-operating expenses for the year ended December 31, 2022. Additionally, the year ended December 31, 2022 included. For the year ended December 31, 2021 corporate and other included stock-based compensation, depreciation, changes in fair value of the convertible debentures and investment impairment of $131, $98, $21,703, and $400 respectively. See Notes 5, 6, 7, 9 and 11 for additional information.